GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Experimental Oral Rinse 1Device: Experimental Oral Rinse 2Other: Placebo Oral RinseDrug: Fluoride toothpaste
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT02753075
- Locations
- πΊπΈ
GSK Investigational Site, Fort Wayne, Indiana, United States
Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSV vaccine GSK3003891ABiological: Boostrix
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 102
- Registration Number
- NCT02753413
- Locations
- π§πͺ
GSK Investigational Site, Wilrijk, Belgium
Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT02752958
- Locations
- π¬π§
GSK Investigational Site, Widnes, Cheshire, United Kingdom
Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease
- Conditions
- Gingivitis
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 253
- Registration Number
- NCT02750943
- Locations
- πΊπΈ
GSK Investigational Site, Las Vegas, Nevada, United States
Efficacy of Three Toothpastes Using an in Situ Caries Model
- Conditions
- Dental Caries
- Interventions
- Drug: 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm FOther: 0 ppm FDrug: 0.425 % w/w phytate,1150ppm FDrug: 0.85 % w/w phytate,1150ppm FDrug: 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT02751320
- Locations
- πΊπΈ
GSK Investigational Site, Indianapolis, Indiana, United States
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT02751424
- Locations
- π¦πΊ
GSK Investigational Site, Adelaide, South Australia, Australia
A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution
- Conditions
- Malaria, Vivax
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT02751294
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity(DH)
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Stannous Fluoride dentificeOther: Sodium Monofluorophosphate dentifrice
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 263
- Registration Number
- NCT02751450
- Locations
- π¬π§
GSK Investigational Site, Bristol, United Kingdom
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Device: Auto-injector
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT02750930
- Locations
- πΊπΈ
GSK Investigational Site, Shavano Prk, Texas, United States
Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 104
- Registration Number
- NCT02742766
- Locations
- π¦πΊ
GSK Investigational Site, Melbourne, Victoria, Australia